Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18174 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Chan Xie. Institution: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Major MEDLINE topics: Antiviral Agents. 8 references.
Abstract (original language)
LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID profiles: Chan Xie
Cite
APA
Xie, C. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18174
Vancouver
Xie C. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18174
BibTeX
@article{Xie2024,
author = {Xie, Chan},
title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18174}
}
EUVIMED